Aronson N E, Wortmann G W, Johnson S C, Jackson J E, Gasser R A, Magill A J, Endy T P, Coyne P E, Grogl M, Benson P M, Beard J S, Tally J D, Gambel J M, Kreutzer R D, Oster C N
Walter Reed Army Medical Center, Washington, D.C. 20307-5001, USA.
Clin Infect Dis. 1998 Dec;27(6):1457-64. doi: 10.1086/515027.
The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg.d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.
报告了葡萄糖酸锑钠（SSG）以20mg/（kg·d）的剂量给药20天（用于治疗皮肤疾病）或28天（用于治疗内脏、黏膜或亲内脏疾病）治疗利什曼病的疗效和毒性。96名经寄生虫学确诊为利什曼病的美国国防部医疗保健受益人被前瞻性随访1年。1名患者感染了人类免疫缺陷病毒；除此之外，无合并症。83例皮肤疾病患者中有91%临床治愈，13例内脏/亲内脏疾病患者中有93%临床治愈。不良反应常见，28%的病例需要中断治疗，但一般为可逆性。这些不良反应包括关节痛和肌痛（58%）、胰腺炎（97%）、转氨酶升高（67%）、头痛（22%）、血液学抑制（44%）和皮疹（9%）。未发现后续发生黏膜利什曼病的病例，也没有因葡萄糖酸锑钠或利什曼病导致的死亡病例。
